Cargando…

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines

PURPOSE: First-generation somatostatin analogs, octreotide (OCT) and lanreotide, are the cornerstone for the medical treatment of growth hormone (GH)-secreting pituitary tumors. A new multireceptor analog, such as pasireotide (PAS), showed better activity than OCT in long-term treatment of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dicitore, A., Saronni, D., Gaudenzi, G., Carra, S., Cantone, M. C., Borghi, M. O., Persani, L., Vitale, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741688/ https://www.ncbi.nlm.nih.gov/pubmed/34128215 http://dx.doi.org/10.1007/s40618-021-01609-1

Ejemplares similares

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
por: Dicitore, Alessandra, et al.
Publicado: (2023)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
por: Carra, Silvia, et al.
Publicado: (2022)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

The role of somatostatin analogues in treatment of TSH secreting pituitary adenomas
por: Zgliczyński, Wojciech, et al.
Publicado: (2013)

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
por: Maiza, Jean Christophe, et al.
Publicado: (2007)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas
por: Araujo-Castro, Marta, et al.
Publicado: (2020)

Stereotactic Irradiation of GH-Secreting Pituitary Adenomas
por: Minniti, G., et al.
Publicado: (2012)

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

Synchronous GH- and prolactin-secreting pituitary adenomas
por: Rahman, Maryam, et al.
Publicado: (2014)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review
por: Kurahashi, Kiyoe, et al.
Publicado: (2017)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas
por: Giuffrida, Giuseppe, et al.
Publicado: (2022)

Dense calcification in a GH-secreting pituitary macroadenoma
por: Ibrahim, Ramez, et al.
Publicado: (2014)

Receptor-bound somatostatin and epidermal growth factor are processed differently in GH4C1 rat pituitary cells
Publicado: (1986)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
por: Liu, Wenjuan, et al.
Publicado: (2017)

Differential expression of microRNAs in GH-secreting pituitary adenomas
por: Mao, Zhi-Gang, et al.
Publicado: (2010)

SAT-255 Pituitary Adenoma With TSH and GH Co Secretion
por: Riquelme, Romina, et al.
Publicado: (2020)

Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma
por: Lin, Ben, et al.
Publicado: (2022)

Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas
por: Wang, Ji-wen, et al.
Publicado: (2014)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

PMON129 Pituitary Adenoma Co-Secreting GH, Prolactin and ACTH
por: Wilson, Sarah, et al.
Publicado: (2022)

Outcome of Endoscopic Transsphenoidal Surgery in Combination with Somatostatin Analogues in Patients with Growth Hormone Producing Pituitary Adenoma
por: Zhou, Tao, et al.
Publicado: (2014)

Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells
por: Rui, Qiu Hong, et al.
Publicado: (2019)

The multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomes
por: Buliman, A, et al.
Publicado: (2016)

Regulated resurfacing of a somatostatin receptor storage compartment fine-tunes pituitary secretion
por: Alshafie, Walaa, et al.
Publicado: (2019)

Effect of long-term administration of somatostatin analogue on renal enlargement in uninephrectomized-diabetic rats.
por: Kim, Y. S., et al.
Publicado: (1993)

Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes
por: Blum, Werner F., et al.
Publicado: (2018)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

Somatostatin Analogues for Receptor Targeted Photodynamic Therapy
por: Kaščáková, Slávka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cdmoeu55rb8pvam7e9v4np8rkm